Validation of the SCID-hu Thy/Liv Mouse Model with Antiretrovirals
Author Information
Author(s): Cheryl A. Stoddart, Cheryl A. Bales, Jennifer C. Bare, George Chkhenkeli, Sofiya A. Galkina, April N. Kinkade, Mary E. Moreno, José M. Rivera, Rollie E. Ronquillo, Barbara Sloan, Paul L. Black
Primary Institution: Gladstone Institute of Virology and Immunology, University of California at San Francisco
Hypothesis
Does the SCID-hu Thy/Liv mouse model predict antiretroviral efficacy in humans for representatives of all four classes of currently licensed drugs?
Conclusion
This highly reproducible mouse model is likely to predict clinical antiviral efficacy in humans.
Supporting Evidence
- Second-generation antiretrovirals were more potent than first-generation drugs.
- 3TC treatment reduced HIV-1 RNA by 94%–99% in treated mice.
- The model allows for head-to-head comparisons of drug efficacy.
- Viral replication in the model was genetically stable.
- Effective dosing levels in mice were comparable to those used in humans.
Takeaway
Scientists used special mice with human organs to test HIV drugs and found that newer drugs work better than older ones.
Methodology
The study involved using SCID-hu Thy/Liv mice implanted with human fetal thymus and liver, followed by treatment with various antiretrovirals and assessment of viral load and thymocyte depletion.
Limitations
The study is limited to the specific conditions of the SCID-hu Thy/Liv mouse model and may not fully replicate human responses.
Participant Demographics
Mice were implanted with human fetal tissues from a single donor.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website